| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
PRATOSARTAN manufacturers
- Pratosartan
-
- $2790.00
-
2026-05-21
- CAS:153804-05-8
- Purity:
- Supply Ability: 10g
|
| | PRATOSARTAN Basic information |
| Product Name: | PRATOSARTAN | | Synonyms: | PRATOSARTAN;FW 7203;4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- | | CAS: | 153804-05-8 | | MF: | C25H26N6O | | MW: | 426.51 | | EINECS: | | | Product Categories: | | | Mol File: | 153804-05-8.mol |  |
| | PRATOSARTAN Chemical Properties |
| Boiling point | 692.9±65.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 4.15±0.10(Predicted) |
| | PRATOSARTAN Usage And Synthesis |
| Uses | Pratosartan is a selective angiotensin II receptor antagonist. | | Definition | ChEBI: Pratosartan is a biphenylyltetrazole. It has a role as an antihypertensive agent. | | References | [1] Sonegawa M, et al. Synthesis and pharmacological activity of the metabolites of Pratosartan. Chem Pharm Bull (Tokyo). 2006 Jun;54(6):782-7. DOI:10.1248/cpb.54.782
[2] Ogihara T, et al. Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7. DOI:10.1291/hypres.31.281 |
| | PRATOSARTAN Preparation Products And Raw materials |
|